KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short-term Investments: 2022-2024

Historic Short-term Investments for Castle Biosciences (CSTL) over the last 3 years, with Dec 2024 value amounting to $173.4 million.

  • Castle Biosciences' Short-term Investments rose 9.29% to $202.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.0 million, marking a year-over-year increase of 9.29%. This contributed to the annual value of $173.4 million for FY2024, which is 20.22% up from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Short-term Investments is $173.4 million, which was up 20.22% from $144.3 million recorded in FY2023.
  • Castle Biosciences' Short-term Investments' 5-year high stood at $173.4 million during FY2024, with a 5-year trough of $135.7 million in FY2022.
  • In the last 3 years, Castle Biosciences' Short-term Investments had a median value of $144.3 million in 2023 and averaged $151.1 million.
  • Data for Castle Biosciences' Short-term Investments shows a peak YoY rose of 20.22% (in 2024) over the last 5 years.
  • Over the past 3 years, Castle Biosciences' Short-term Investments (Yearly) stood at $135.7 million in 2022, then grew by 6.32% to $144.3 million in 2023, then increased by 20.22% to $173.4 million in 2024.